Clinical Trial Update: Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase 2 trial investigating eculizumab, a complement inhibitor, to overcome platelet transfusion refractoriness in patients with severe thrombocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alloimmune Platelet Refractoriness
• Thrombocytopenia

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Thrombocytopenia, Alloimmune Platelet Refractoriness | Phase 2 | Status: COMPLETED | Results posted: 2019-01-03